Project Grant R16AI201458
Award Date 9/3/26
Completion Date 8/31/30
Dollars Obligated $148K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
DeKalb, IL, USA
Similar Awards
- The National Institute of Allergy and Infectious Diseases awarded the University of Illinois $3,068,770 on August 12, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop neuraminidase-based influenza vaccines with broad protective immunity. The research systematically analyzes the structure-function relationships of neuraminidase monoclonal antibodies, maps the affinity maturation pathways leading to broadly protective antibodies, and engineers a broadly...
- The National Institute of Allergy and Infectious Diseases awarded the University of Illinois $236,407 on September 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate the structural basis of ARMA-mediated resistance to aminoglycoside antibiotics targeting the bacterial ribosome. The research addresses how ARMA methyltransferases confer high-level resistance to aminoglycosides—a cornerstone class of ribosome-binding antibacterial drugs used...
- The National Institute of Allergy and Infectious Diseases awarded the University of Illinois $620,662 on July 2, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to fund research into mechanisms by which quorum-sensing-active Streptococcus pyogenes suppress innate immune responses in macrophages. The research addresses how GAS strains in a quorum-sensing-on state prevent transcription of pro-inflammatory genes despite activation of upstream NF-κB signaling pathways,...
- The National Institute of Allergy and Infectious Diseases awarded Trustees of Indiana University $435,875 on June 9, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop methods for assessing gene function in Culicoides biting midges and test RNA interference–based insect gene silencing as a control mechanism for these disease vectors. The research will evaluate interfering RNA produced and delivered in Saccharomyces cerevisiae yeast to silence genes in...
- The National Institute of Allergy and Infectious Diseases awarded Loyola University of Chicago Health Sciences Campus $462,000 on August 18, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to conduct research on mechanistic understanding of influenza virus inhibition by non-canonical ISG15. The research examines how alternative splicing of the interferon-stimulated gene ISG15 produces novel transcript isoforms that inhibit influenza virus replication. The project...
- The National Institute of Allergy and Infectious Diseases awarded Northwestern University $725,778 on August 19, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate alphaherpesvirus axonal transport and neuroinvasion mechanisms. The research deciphers how neuroinvasive herpesviruses such as herpes simplex virus type 1 and pseudorabies virus invade the nervous system to establish lifelong latent infections; identifies intrinsic barriers to neural...
- The National Institute of Allergy and Infectious Diseases awarded the University of Illinois $790,913 on July 13, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to define the molecular and cellular mechanisms by which gut commensal microbiota-specific T cells drive intestinal and neuroinflammation. The project investigates how segmented filamentous bacteria (SFB)-specific CD4 T cells, initially generated in gut-draining mesenteric lymph nodes and intestines in...
- The National Institute of Allergy and Infectious Diseases awarded The University of Chicago $451,000 on February 5, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to identify novel cellular targets for enhancing targeted RNA degradation in antiviral therapies. The project addresses a critical limitation in ribonuclease-targeting chimeras (RIBOTACs), which degrade viral RNA to prevent replication but achieve only approximately 75% maximum degradation of target...
- The National Institute of Allergy and Infectious Diseases awarded the University of Illinois $736,822 on February 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate how bacterial lipases drive host immunity and physiology during infection. The research focuses on Staphylococcus aureus lipases, particularly the secreted lipase GEH, which the recipient's laboratory has shown inhibits activation of innate immune cells and blunts pro-inflammatory...
- The National Institute of Allergy and Infectious Diseases awarded the University of Illinois $226,768 on May 5, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate the role of Cryptosporidium secretory effector proteins in manipulating host actin polymerization during parasite invasion. Cryptosporidium is a leading cause of diarrheal disease and death in young children and immunocompromised individuals, with no effective vaccines or drugs for...